skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

15319

Clinical utility of varenicline for smokers with medical and psychiatric comorbidity



Review

(5230) Total Article Views


Authors: Jon O Ebbert, Kirk D Wyatt, Ali Zirakzadeh, et al

Published Date November 2009 Volume 2009:4 Pages 421 - 430
DOI: http://dx.doi.org/10.2147/COPD.S6300

Jon O Ebbert, Kirk D Wyatt, Ali Zirakzadeh, Michael V Burke, JT Hays

Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN, USA

Abstract: Chronic obstructive pulmonary disease (COPD) is a costly and deadly disease afflicting an estimated 210 million people and accounting for 5% of all global deaths. Exposure to cigarette smoke is the greatest risk factor for COPD in the developed world. Smoking cessation improves respiratory symptoms and lung function and reduces mortality among patients with COPD. Cigarette smokers with COPD and other co-morbid conditions such as cardiovascular disease and psychiatric illnesses should receive comprehensive tobacco treatment interventions incorporating efficacious pharmacotherapies. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, is the newest and most effective drug currently available to promote smoking cessation. In conjunction with behavioral interventions and clinical monitoring for potential side effects, varenicline offers great hope for reducing smoking-attributable death and disability.

Keywords: smoking cessation, chronic obstructive pulmonary disease, varenicline




Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter

 

Other articles by Dr Jon Ebbert


Readers of this article also read:

  • Journal Indexing

    See where all the Dove Press journals are indexed.

  • Testimonials

    "I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University.

  • MLA'14 -

    May 16–21, 2014
    Chicago

  • ERS Int'l Congress

    6 - 10 September, 2014
    Munich, Germany

  • CHEST 2014

    25 - 30 October, 2014
    Austin, Texas